Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

Why We Need Fast-Acting Anxiety Relief Now More Than Ever Anxiety isn’t just feeling nervous before a big event—it can be relentless, overwhelming, and even debilitating. Traditional treatments like ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Leerink Partners analyst Marc Goodman has maintained their bullish stance on MNMD stock, giving a Buy rating yesterday.Invest with Confidence: ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.